Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

•CF is the best palliative regimen in adv. ESCC.•Panitumumab added to CF failed to improve survival.•Low sEGFR linked to better PFS. BackgroundPalliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor recep...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autors principals:	Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas Jens Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller, Manfred P. Lutz, Florian Lordick, María Alsina, K Borchert, Richard Greil, Wolfgang Eisterer, Arno Schad, Julia Slotta‐Huspenina, Eric Van Cutsem, Sylvie Lorenzen
Format:	Artigo
Idioma:	anglès
Publicat:	2020
Accés en línia:	https://doi.org/10.1016/j.annonc.2019.10.018
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
per: Thomaidis, Thomas, et al.
Publicat: (2014)

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
per: Markus Moehler, et al.
Publicat: (2016)

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
per: Moehler, Markus, et al.
Publicat: (2016)

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
per: S-E. Al-Batran, et al.
Publicat: (2017)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
per: Tintelnot, Joseph, et al.
Publicat: (2020)

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
per: Sylvie Lorenzen, et al.
Publicat: (2009)

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
per: Kripp, Melanie, et al.
Publicat: (2017)

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
per: Hans‐Joachim Schmoll, et al.
Publicat: (2020)

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial
per: Stein, Alexander, et al.
Publicat: (2022)

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
per: Peter Thuss‐Patience, et al.
Publicat: (2012)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
per: Lorenzen, Sylvie, et al.
Publicat: (2020)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
per: Sylvie Lorenzen, et al.
Publicat: (2020)

Aios in coronatijd
per: Maria Greijn, Claudia, et al.
Publicat: (2020)

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
per: Dorothea Wagner, et al.
Publicat: (2019)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
per: Hoehler, T, et al.
Publicat: (2013)

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
per: Wagner, Anna Dorothea, et al.
Publicat: (2019)

HER2 testing in gastric cancer: results of a German expert meeting
per: Florian Lordick, et al.
Publicat: (2017)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
per: Thomas Jens Ettrich, et al.
Publicat: (2018)

HER2 testing in gastric cancer: results of a German expert meeting
per: Lordick, Florian, et al.
Publicat: (2017)

Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer
per: Diefenhardt, Markus, et al.
Publicat: (2019)

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy
per: Sylvie Lorenzen, et al.
Publicat: (2013)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
per: Ettrich, Thomas J., et al.
Publicat: (2018)

AIOS proceedings: A response
per: Rajendran, Babu
Publicat: (2009)

Panitumumab
per: Dubois, Eline A, et al.
Publicat: (2009)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
per: Lordick, F, et al.
Publicat: (2010)

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
per: Schimanski, Carl Christoph, et al.
Publicat: (2020)

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
per: Al-Batran, Salah-Eddin, et al.
Publicat: (2017)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
per: Florian Lordick, et al.
Publicat: (2010)

Panitumumab (Vectibix)
per: Gemmete, J.J., et al.
Publicat: (2011)

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
per: Al-Batran, Salah-Eddin, et al.
Publicat: (2017)

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
per: Salah‐Eddin Al‐Batran, et al.
Publicat: (2017)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
per: Karthaus, Meinolf, et al.
Publicat: (2016)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
per: Modest, Dominik Paul, et al.
Publicat: (2022)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
per: Kurreck, A., et al.
Publicat: (2020)

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG
per: Kozo Kataoka, et al.
Publicat: (2017)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
per: Thaler, Josef, et al.
Publicat: (2012)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
per: Sommerhäuser, G., et al.
Publicat: (2022)

Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population
per: Sebastian Stintzing, et al.
Publicat: (2014)

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
per: Koessler, Thibaud, et al.
Publicat: (2021)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
per: Stintzing, S, et al.
Publicat: (2019)